ID   MWCL-1/BR
AC   CVCL_VJ31
DR   cancercelllines; CVCL_VJ31
DR   Wikidata; Q95991589
RX   PubMed=25382610;
RX   PubMed=28548645;
CC   Selected for resistance to: ChEBI; CHEBI_52717; Bortezomib (Velcade).
CC   Sequence variation: Mutation; HGNC; HGNC:7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Hemizygous (from parent cell line).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C80307; Waldenstrom macroglobulinemia
DI   ORDO; Orphanet_33226; Waldenstrom macroglobulinemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M086 ! MWCL-1
SX   Male
AG   73Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 19-12-24; Version: 10
//
RX   PubMed=25382610; DOI=10.1038/bcj.2014.74; PMCID=PMC5424099;
RA   Chitta K.S., Paulus A., Caulfield T.R., Akhtar S., Blake M.K.K.,
RA   Ailawadhi S., Knight J., Heckman M.G., Pinkerton A.B., Chanan-Khan A.A.;
RT   "Nimbolide targets BCL2 and induces apoptosis in preclinical models of
RT   Waldenstroms macroglobulinemia.";
RL   Blood Cancer J. 4:e260.1-e260.10(2014).
//
RX   PubMed=28548645; DOI=10.1038/bcj.2017.40; PMCID=PMC5518884;
RA   Paulus A., Akhtar S., Yousaf H.M., Manna A., Paulus S.M., Bashir Y.,
RA   Caulfield T.R., Blake M.K.K., Chitta K.S., Wang X., Asmann Y.,
RA   Hudec R., Springer W., Ailawadhi S., Chanan-Khan A.A.;
RT   "Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or
RT   CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through
RT   upregulation of Bcl-2 and AKT resulting in vulnerability towards
RT   venetoclax or MK2206 treatment.";
RL   Blood Cancer J. 7:e565.1-e565.11(2017).
//